Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. - Wikidata - thesis-toulmin - TriplyDB

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma.

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma.

http://www.wikidata.org/entity/Q37528784

about

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.Melanoma treatment in review.

P2860

Q55206910-A17985C3-3DC6-4F37-AF8E-F8968E1BF446 Q55217220-8146A9E9-8D31-4716-BAD2-30C5A881B497

P2860

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma.

http://www.wikidata.org/entity/Q37528784

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Metastasectomy Following Immun ...... tients with Advanced Melanoma.

@en

Metastasectomy Following Immun ...... tients with Advanced Melanoma.

@nl

type

label

Metastasectomy Following Immun ...... tients with Advanced Melanoma.

@en

Metastasectomy Following Immun ...... tients with Advanced Melanoma.

@nl

prefLabel

Metastasectomy Following Immun ...... tients with Advanced Melanoma.

@en

Metastasectomy Following Immun ...... tients with Advanced Melanoma.

@nl

P1433

Q37528784-46908E8D-FB0F-4B51-A287-F73F9D6AB258

P1476

Q37528784-82269899-B843-4811-B742-AFB7C77CF794

P2093

Q37528784-25081CFC-13A6-43BD-AF92-3118A73E8BD5

Q37528784-33DFF1E3-258F-4B5E-9BA3-09C32AC72586

Q37528784-3B273115-5EE4-4825-8466-6FC15AF07999

Q37528784-445C64CA-A837-46DE-AB42-56F9AC1940A7

Q37528784-8D69CC73-CFE5-455C-990B-37D3BE35A47D

Q37528784-A5BA2DB2-8D76-448E-AAD0-6C810E61593B

Q37528784-AF21E852-CF79-42BA-BF2B-3DA77DF6A9A0

Q37528784-FC673053-A775-4CC5-BAB8-CC5F13FA8856

P2860

Q37528784-0D6DE83F-E401-40CA-8898-71627E5DF74A

Q37528784-1D88C030-35EB-4A62-91ED-A76AA75099DA

Q37528784-32A4AEBA-F839-4701-81EB-2A0D6ABBB8BD

Q37528784-43603697-AF97-4D0D-90C6-85846CEB31E6

Q37528784-4813F22F-D017-46A7-990C-54B54E3ED78B

Q37528784-6F9F9479-F2FE-4F22-9F21-96B6CF484639

Q37528784-71021E93-C6FF-462F-A13B-39B2D048EBDF

Q37528784-A8D4A328-B5A1-47FF-99D4-E108BDE7ED07

Q37528784-AB3B195B-ECED-4A31-A7E8-00D668B929AE

Q37528784-B1FC2DE4-6D33-46AC-AFB2-C31DC69BF183

P2888

Q37528784-DC8C8F93-76B0-4CF2-B8DE-AE69B2EDE292

P304

Q37528784-2DFB5C69-D3B2-426A-AA2C-D6EDEFDC87A8

P31

Q37528784-339C80CE-AFDE-4052-B935-37010582A31D

P356

Q37528784-9714936B-659D-4037-B9F8-F91510A6F098

P433

Q37528784-ACB2886E-D238-4C64-B55F-993A8EA9AA86

P478

Q37528784-859C3227-296D-44DA-BA43-3A3F2F951763

P50

Q37528784-E3D2929E-BEC1-46DA-AA24-C98052D7089E

P577

Q37528784-7E571CE0-EE16-4F6C-838C-1F48F8E3331D

P6179

Q37528784-BB84A032-F9B8-411D-B770-7448F6624408

P698

Q37528784-45FA5C1C-9667-446B-8BBF-AFCDAD94FCC5

P921

Q37528784-1984DEFC-00F2-45E9-8982-96873C829B2E

P932

Q37528784-BACA924A-D344-4459-8B9C-D59BE44F83A1

P356

S10434-016-5537-0

P1433

Annals of Surgical Oncology

P1476

Metastasectomy Following Immun ...... atients with Advanced Melanoma

@en

P2093

David S Schrump

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Nicholas D Klemen

http://www.w3.org/2001/XMLSchema#string

Richard M Sherry

http://www.w3.org/2001/XMLSchema#string

Stephanie L Goff

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Udai S Kammula

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Cancer regression in patients after transfer of genetically engineered lymphocytes

Nivolumab plus ipilimumab in advanced melanoma.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

P2888

s10434-016-5537-0

P304

135-141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-016-5537-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Paul L Feingold

P577

2016-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026233646

http://www.w3.org/2001/XMLSchema#string

P698

27638681

http://www.w3.org/2001/XMLSchema#string

P921

P932

5179591

http://www.w3.org/2001/XMLSchema#string